Rexlemestrocel-L has no CRL's so who is it that has their head in the sand ?
You would also be aware of the differences in the two treatments given you claim to know so much and as I have said all along they would get the nod from the FDA for an AA pathway for Revascor (aka Rexlemestrocel-L) for CHF and of course they did earlier this year
Let us know what Gregory George says when you call him to share all of your wisdom of the flaws in Mesoblast's treatments from the limited publicly known information ?
Rexlemestrocel-L has no CRL's so who is it that has their head...
-
- There are more pages in this discussion • 760 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |